Uihlein Richard E 4

4 · GALECTIN THERAPEUTICS INC · Filed Sep 27, 2023

Form 4

Period: 2023-09-26

Director10% Owner

Transactions

Exercise/Conversion
Common Stock
2023-09-26$5.00/sh+170,000$850,000→ 9,635,495 total
Exercise/Conversion
Common Stock
2023-09-26$3.26/sh+200,000$652,000→ 10,035,495 total
Exercise/Conversion
Common Stock Purchase Warrant (right to buy)
2023-09-26−200,000→ 0 total
Exercise: $3.26From: 2023-03-31Exp: 2029-07-31→ Common Stock (200,000 underlying)
Exercise/Conversion
Common Stock Purchase Warrant (right to buy)
2023-09-26−1,466,204→ 0 total
Exercise: $5.00From: 2017-06-22Exp: 2023-12-23→ Common Stock (1,466,204 underlying)
Exercise/Conversion
Common Stock Purchase Warrant (right to buy)
2023-09-26−170,000→ 330,000 total
Exercise: $5.00From: 2022-07-25Exp: 2029-07-31→ Common Stock (170,000 underlying)
Exercise/Conversion
Common Stock Purchase Warrant (right to buy)
2023-09-26−200,000→ 0 total
Exercise: $3.00From: 2023-06-30Exp: 2029-07-31→ Common Stock (200,000 underlying)
Exercise/Conversion
Common Stock
2023-09-26$5.00/sh+1,466,204$7,331,020→ 9,466,495 total
Exercise/Conversion
Common Stock
2023-09-26$3.00/sh+200,000$600,000→ 9,835,495 total
Exercise/Conversion
Common Stock
2023-09-26$3.00/sh+200,000$600,000→ 10,235,495 total
Exercise/Conversion
Common Stock Purchase Warrant (right to buy)
2023-09-26−200,000→ 0 total
Exercise: $3.00From: 2022-12-19Exp: 2029-07-31→ Common Stock (200,000 underlying)

Holdings

Footnotes (1)

[F1]The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.

Documents

1 file